Tissue Factor, Blood Coagulation, and Beyond: an Overview

Overview

Journal Int J Inflam

Publisher Wiley

Date 2011 Sep 24

PMID 21941675

Citations 83

Authors

Arthur J Chu

Affiliations

Soon will be listed here.

Abstract

Emerging evidence shows a broad spectrum of biological functions of tissue factor (TF). TF classical role in initiating the extrinsic blood coagulation and its direct thrombotic action in close relation to cardiovascular risks have long been established. TF overexpression/hypercoagulability often observed in many clinical conditions certainly expands its role in proinflammation, diabetes, obesity, cardiovascular diseases, angiogenesis, tumor metastasis, wound repairs, embryonic development, cell adhesion/migration, innate immunity, infection, pregnancy loss, and many others. This paper broadly covers seminal observations to discuss TF pathogenic roles in relation to diverse disease development or manifestation. Biochemically, extracellular TF signaling interfaced through protease-activated receptors (PARs) elicits cellular activation and inflammatory responses. TF diverse biological roles are associated with either coagulation-dependent or noncoagulation-mediated actions. Apparently, TF hypercoagulability refuels a coagulation-inflammation-thrombosis circuit in "autocrine" or "paracrine" fashions, which triggers a wide spectrum of pathophysiology. Accordingly, TF suppression, anticoagulation, PAR blockade, or general anti-inflammation offers an array of therapeutical benefits for easing diverse pathological conditions.

Citing Articles

Circulating extracellular vesicles and neutrophil extracellular traps contribute to endothelial dysfunction in preeclampsia.

Ramos A, Youssef L, Molina P, Torramade-Moix S, Martinez-Sanchez J, Moreno-Castano A Front Immunol. 2024; 15:1488127.

PMID: 39735539 PMC: 11671372. DOI: 10.3389/fimmu.2024.1488127.

Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art.

Camarda F, Paderno M, Cannizzaro M, Nero C, Sabatucci I, Fuca G Ther Adv Med Oncol. 2024; 16:17588359241277647.

PMID: 39323928 PMC: 11423367. DOI: 10.1177/17588359241277647.

Association between baseline lipid profile and risk of worsening in patients with myasthenia gravis: A retrospective cohort study.

Zhang Y, Wen Z, Xia C, Chen M, Cai F, Chu L Heliyon. 2024; 10(17):e36737.

PMID: 39281610 PMC: 11402134. DOI: 10.1016/j.heliyon.2024.e36737.

Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.

Malik S, Sikander M, Bell N, Zubieta D, Bell M, Yallapu M J Ovarian Res. 2024; 17(1):161.

PMID: 39118097 PMC: 11308542. DOI: 10.1186/s13048-024-01485-2.

The differential formation and composition of leukocyte-platelet aggregates induced by various cellular stimulants.

Peshkova A, Saliakhutdinova S, Sounbuli K, Selivanova Y, Andrianova I, Khabirova A Thromb Res. 2024; 241:109092.

PMID: 39024901 PMC: 11411814. DOI: 10.1016/j.thromres.2024.109092.

References

Gerrits A, Koekman C, Yildirim C, Nieuwland R, Akkerman J . Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost. 2008; 7(1):198-205. DOI: 10.1111/j.1538-7836.2008.03206.x. View

Wakefield T, Strieter R, Wilke C, Kadell A, Wrobleski S, Burdick M . Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol. 1995; 15(2):258-68. DOI: 10.1161/01.atv.15.2.258. View

MacLean P, Tait R, Rumley A, McMahon A, Lowe G . Anticoagulation with warfarin downregulates inflammation. J Thromb Haemost. 2003; 1(8):1838-9. DOI: 10.1046/j.1538-7836.2003.t01-1-00372.x. View

Ettelaie C, Su S, Li C, Collier M . Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. Microvasc Res. 2008; 76(3):152-60. DOI: 10.1016/j.mvr.2008.07.007. View

Ott I . Tissue factor in acute coronary syndromes. Semin Vasc Med. 2004; 3(2):185-92. DOI: 10.1055/s-2003-40676. View

Minnema M, Chang A, Jansen P, Lubbers Y, Pratt B, Whittaker B . Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000; 95(4):1117-23. View

Frentzou G, Collier M, Seymour A, Ettelaie C . Differential induction of cellular proliferation, hypertrophy and apoptosis in H9c2 cardiomyocytes by exogenous tissue factor. Mol Cell Biochem. 2010; 345(1-2):119-30. DOI: 10.1007/s11010-010-0565-8. View

Roche N, Stirling R, Lim S, Oliver B, Chung K . Regulation of protease-activated receptor-1 in mononuclear cells by neutrophil proteases. Respir Med. 2003; 97(3):228-33. DOI: 10.1053/rmed.2003.1437. View

Guimaraes A, Rijken D . Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thromb Haemost. 2004; 91(3):473-9. DOI: 10.1160/TH03-06-0377. View

10.

Pang I, Iwasaki A . Inflammasomes as mediators of immunity against influenza virus. Trends Immunol. 2010; 32(1):34-41. PMC: 3017631. DOI: 10.1016/j.it.2010.11.004. View

11.

Johnson K, Choi Y, DeGroot E, SAMUELS I, Creasey A, Aarden L . Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol. 1998; 160(10):5130-5. View

12.

Kaiser B, Jeske W, Walenga J, Fareed J . Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinolysis. 2000; 10(8):495-501. DOI: 10.1097/00001721-199912000-00007. View

13.

Gruber A, Hanson S, Kelly A, Yan B, Bang N, Griffin J . Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990; 82(2):578-85. DOI: 10.1161/01.cir.82.2.578. View

14.

Solovey A, Kollander R, Shet A, Milbauer L, Choong S, Panoskaltsis-Mortari A . Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004; 104(3):840-6. DOI: 10.1182/blood-2003-10-3719. View

15.

Camino-Lopez S, Badimon L, Gonzalez A, Canals D, Pena E, Llorente-Cortes V . Aggregated low density lipoprotein induces tissue factor by inhibiting sphingomyelinase activity in human vascular smooth muscle cells. J Thromb Haemost. 2009; 7(12):2137-46. DOI: 10.1111/j.1538-7836.2009.03638.x. View

16.

Wong P, Luettgen J, Rendina A, Kettner C, Xin B, Knabb R . BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies. Thromb Haemost. 2010; 104(2):261-9. DOI: 10.1160/TH10-01-0025. View

17.

Franchi L, Munoz-Planillo R, Reimer T, Eigenbrod T, Nunez G . Inflammasomes as microbial sensors. Eur J Immunol. 2010; 40(3):611-5. DOI: 10.1002/eji.200940180. View

18.

Derian C, Damiano B, Addo M, Darrow A, DAndrea M, Nedelman M . Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003; 304(2):855-61. DOI: 10.1124/jpet.102.042663. View

19.

Liu M, Reilly M, Casasanto P, McKenzie S, Williams K . Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. Arterioscler Thromb Vasc Biol. 2006; 27(2):430-5. PMC: 4568121. DOI: 10.1161/01.ATV.0000254674.47693.e8. View

20.

Chu A . Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct. 2004; 24(2):173-92. DOI: 10.1002/cbf.1200. View